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abstract
PURPOSE Radiotherapy (RT) is an essential component of cancer treatment. There is a lack of RT services in
sub-Saharan Africa as well as limited knowledge regarding clinical practices. The purpose of this study was to
identify and describe the patterns for RT treatment in Ethiopia.
METHODS AND MATERIALS We performed a retrospective analysis of 1,823 patients treated with cobalt RT at
a large referral hospital in Addis Ababa, Ethiopia, from May 2015 through January 2018. Paper charts were
reviewed for patient and treatment characteristics. Descriptive statistics were computed using SPSS (IBM,
Armonk, NY).
RESULTS Among patients treated for cancer, 98% (n = 1,784) were adults, 78% (n = 1,426) were female, 5%
(n = 85) were HIV positive, 30% (n = 555) were from Addis Ababa, and the median age was 48 years
(interquartile range [IQR], 38-58 years). Cervical cancer was the most frequent cancer treated (47%, n = 851),
followed by breast cancer (15%, n = 274) and head and neck cancer (10%, n = 184). Seventy-three percent of
patients (n = 1,339) presented at a late stage, and 62% (n = 1,138) received palliative RT. The wait times were
the shortest for patients receiving palliative treatment (median, 0 days; IQR, 0-15 days; n = 1,138), whereas wait
times were longer for patients receiving curative treatment (median, 150 days; IQR, 60-210 days; n = 685).
Three percent of patients (n = 56) had documented grade 3 or 4 acute toxicity; of these, 59% (n = 33) were
patients with head and neck cancer.
CONCLUSION Cervical cancer accounted for half of patients treated; thus, a majority of patients were adult
females. Most patients had advanced-stage cancer, and goals of care were palliative. Wait times were long for
patients with curative-intent cancer as a result of low capacity for RT services.
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INTRODUCTION
Radiotherapy (RT) plays an important role in oncology
and can be used as the principle treatment method
or combined with other modalities to provide cure in
up to 40% of patients with a variety of cancers.1 RT is
also a highly effective treatment for palliation of can-
cer symptoms.2 In low- and middle-income countries
(LMICs), it is estimated that up to 70% of patients would
beneﬁt from RT at some point in their illness as a result
of its utility in alleviating symptoms of late-stage
disease.3 Moreover, RT is also a cost-effective modal-
ity in LMICs where personnel costs are low.4 Despite the
clear necessity of RT in LMICs, there is stark inequality
in access to care. Nearly 60% of new cancer diagnoses
occur in LMICs, whereas ,40% of RT equipment is
found in these regions.5,6 In sub-Saharan Africa (ex-
cluding southern Africa), the disparity is striking, with
fewer than one RT machine per 1 million population,
10 times lower than that of North America.6 In fact,
more than half the countries in Africa lack a single RT
center.7 Therefore, it is estimated that 700 additional RT
machines are needed to increase capacity to an ac-
ceptable level in Africa.8 This need will only continue to
grow because cancer incidence is projected to double
in lower resourced regions of Africa by 2040.5
Ethiopia is a low-income country in East Africa with one
of the highest populations in sub-Saharan Africa. With
the global health burden shifting from communicable
to noncommunicable diseases, cancer is now a leading
cause of death in Ethiopian adults.9,10 At present, Ethiopia
has one functioning cobalt teletherapy machine, serving
more than 100 million inhabitants. Tikur Anbessa
Specialized Hospital (TASH) in Addis Ababa, the only
oncologic referral center in Ethiopia, opened in 1998
and treats more than 1,700 RT patients a year.11 In the
2016 to 2020 Ethiopian National Cancer Control Plan,
inadequate RT equipment relative to population need
was recognized.12 In response, the government has
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prioritized expanding RT services to 5 regional teaching
hospitals across the country and has committed to pur-
chasing linear accelerators rather than increasing the
number of cobalt machines.
Cancer diagnoses are dramatically increasing in Africa, and
it is evident that RT provides an invaluable tool for cure and
palliation. Because this has been recognized by governments
and investors, there is a broad consideration to increase
availability of RT across the continent. However, few data are
available to understand the current use and dynamics of RT
treatment in Africa, with most studies in the region based on
small or cancer-speciﬁc cohorts. Epidemiology-based cancer
research is pivotal for cancer control planning in all settings
and is particularly critical where resources are limited to
prioritize funding toward evidence-based policies that focus
on highest need.13 The primary aim of this study was to
provide a broad descriptive analysis of the current patterns
of cobalt RT in Ethiopia in a large cohort of patients with
cancer to inform cancer control policy and provide a baseline
for assessing the effectiveness of future RT interventions.
METHODS AND MATERIALS
Study Design and Participants
This retrospective, cross-sectional study included adult
and pediatric patients treated with cobalt RT for malignant
diagnoses between May 2015 and January 2018 at TASH
in Addis Ababa, Ethiopia. It is estimated that 4,250 patients
were treated during the study period, and a random sample
of 1,826 charts (43%) were evaluated. Inclusion of all
patients treated during the study period was not considered
feasible due to difﬁculty locating paper charts from in-
complete registration data in an overcrowded ﬁle room.
Therefore, charts were randomly identiﬁed by hospital ad-
ministrative staff in the RT department.
General demographic information (age, sex, and region),
tumor characteristics (histology and stage), and data re-
garding speciﬁc cancer therapy were extracted from the
patients’ paper ﬁles. Charts of individuals treated with RT
for a benign condition were excluded.
Institutional Characteristics
TASH had one functional cobalt teletherapy unit (Theratron
Equinox, Best Theratronics, Ottawa, Ontario, Canada).
Brachytherapy capacity was added in 2016. There were
6 radiation oncologists and 28 residents by the end of
the study. There were 4 medical physicists, 5 radiation
therapists, and 26 oncology nurses on staff.
Diagnosis, Staging of Cancer, and HIV Status
Histology and diagnoses of cancer (International Classiﬁ-
cation of Diseases–Oncology) were taken from the charts
and grouped into categories modeled after the Interna-
tional Agency for Research on Cancer.5 Advanced imaging
(computed tomography [CT] and magnetic resonance
imaging [MRI]) was available at TASH; however, the bulk of
staging was performed by x-ray and ultrasound. For ex-
ample, staging for advanced breast and cervical cancers
is performed using chest x-ray and abdominal ultrasound.
CT staging was reserved for head and neck, thoracic,
and select GI cancers and sarcomas. MRI was used in
CNS disease, rectal cancer, and select sarcomas.
Staging was classiﬁed by International Federation of Gyne-
cology and Obstetrics (FIGO) classiﬁcation for gynecologic
malignancies, Ann Arbor staging for lymphomas, and
American Joint Committee on Cancer (AJCC) seventh edition
staging for all other cancers except for CNS malignancies
and sarcomas, which were not staged but rather classiﬁed as
operable or inoperable. Multiple myeloma was not staged
because of a lack of molecular proﬁling. The stage at time of
pathologic diagnosis was not collected; therefore, stage was
determined at the planning visit just before initiating RT.
Stage was then classiﬁed as early stage, late stage, locore-
gional recurrence, distant recurrence, not reported, or not
applicable. Early stage was deﬁned as AJCC/Ann Arbor/FIGO
stage I or II or operable for CNSmalignancies and sarcoma.
Late stage was classiﬁed as AJCC/Ann Arbor/FIGO stage III or
IV or inoperable for CNS malignancies and sarcoma. Pres-
ence or absence of distant metastasis was also recorded. The
baseline symptoms were recorded (if present), and self-
reported HIV status was documented as unknown, nega-
tive, positive on highly active antiretroviral therapy (HAART),
or positive not documented to be on HAART.
Cancer Treatment
Patients with cancer were referred from all regions of
Ethiopia and nearby countries (ie, Eritrea and Djibouti) for
RT. Typically patients were referred in a stepwise approach,
CONTEXT
Key Objective There is a paucity of high-quality epidemiological data on radiotherapy utilization patterns in sub-Saharan Africa.
This study seeks to describe current patterns of cobalt radiotherapy in Ethiopia and understand unmet needs.
Knowledge Generated Nearly 2,000 patients were included from the only radiotherapy treating facility in Ethiopia. Cervical
cancer accounted for half of patients treated. Most radiotherapy was palliative and wait times for curative patients were long
due to low capacity for radiotherapy services.
Relevance This study provides important epidemiology-based cancer research highlighting the need for increased radio-
therapy capacity and providing pivotal information on areas of priority for cancer control planning strategies.
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starting at the primary level of care (health center, health
post, or primary hospital); then patients were referred to the
secondary level (general hospital) before being referred
to TASH. At the initial appointment, if RT was indicated,
the patients were either given an appointment to return
for treatment planning or put on a call list because of
high patient volume. Patients with acute symptoms or
impending complications from their disease were given
priority, followed by patients younger than 25 years old.
Treatment aim was assigned at the second visit when
treatment was planned and classiﬁed as curative (radical,
adjuvant, or neoadjuvant) or palliative.
Most treatment planning was performed by anatomic
landmarks, even after June 2018 when a planning CT was
obtained and reserved for selected complicated planning
(ie, approximately 1 of 6 patients with head and neck
cancer) predominately for training purposes. Waiting time
was calculated as the time between the date of the initial
visit and the start of RT (in days). Body site(s) treated, total
dose (grays), number of fractions, and dates of external-
beam treatment were documented, along with use of
brachytherapy when indicated. Any documented acute
toxicities (type and grade) were recorded (assessed at end
of treatment and the recommended 4-week follow-up, al-
though follow-up after that is often sporadic and toxicity not
routinely documented). It was reported whether treatment
was completed as planned, interrupted temporarily but
completed, or discontinued. Whether patients received
chemotherapy and, if so, the timing (before, during, or
after RT) were reported. Concurrent chemotherapy was not
commonly used given long RT wait times.
Statistical Analysis
Descriptive statistical analysis was performed using IBM
SPSS Statistics version 24 (IBM, Armonk, NY).
Ethical and Quality Considerations
Ethical approval was obtained from the Addis Ababa
University Clinical Oncology Department Ethical Review
Board. The data were deidentiﬁed and managed in a se-
curedMicrosoft Excel 2018 v16.18 spreadsheet (Microsoft,
Redmond, WA). The study was conducted without indi-
vidual informed consent because the study relied on ret-
rospective data collected as part of routine patient care.
RESULTS
Cancer Distribution and HIV Status
Of 1,826 patient charts evaluated, 3 were excluded (un-
classiﬁed diagnoses), resulting in 1,823 patients evaluable
and included in this analysis. Patient and general treatment
characteristics are listed in Table 1. Stage at the initiation of
treatment was as follows: 13% not staged (n = 239), 1%
stage I (n = 16), 15% stage II (n = 266), 22% stage III
(n = 407), and 50% stage IV (n = 895). Thus, three quarters
of patients with cancer (n = 1,339) presented at late stage
(stage III-IV and inoperable). Five percent of the total cohort
(n = 85) reported HIV positivity, and the majority were
patients with gynecologic cancer (n = 60, 71% of all
HIV-positive patients). Of these gynecologic patients
with HIV, 70% (n = 42) had stage III or IV disease. Nearly all
HIV-positive patients (n = 83, 98%) reported being treated
with HAART.
Treatment Characteristics
Primary indications for palliative RT included pain (n = 368,
32%), pain and bleeding (n = 261, 23%), bleeding (n =
149, 13%), obstructive symptoms (n = 37, 3%), discharge
TABLE 1. Patient and General Treatment Characteristics (N = 1,823)
Characteristic No. of Patients (%)
Patient age category, years
Pediatric (0-17) 39 (2.1)
Adult (≥ 18) 1,784 (97.9)
Median age, years (IQR) 48 (38-58)
Sex
Female 1,426 (78.2)
Male 397 (21.8)
Region
Addis Ababaa 555 (30.4)
Oromia 553 (30.4)
Amhara 352 (19.3)
SNNPR 170 (9.3)
Tigray 83 (4.6)
Other 80 (4.3)
Not reported 30 (1.6)
HIV status
Unknown 1,667 (91.4)
Positive 85 (4.6)
Negative 71 (3.9)
Cancer diagnosis
Cervical 851 (46.7)
Breast 274 (15.1)
Head and neck 184 (10.1)
Sarcoma 64 (3.5)
Colorectal 57 (3.1)
Thyroid 57 (3.1)
Other 336 (22.6)
Stage
Early (I-II) 334 (18.3)
Late (III-IV) 1,339 (73.5)
Treatment intent
Palliative 1,138 (62.4)
Curative 685 (37.6)
Abbreviations: IQR, interquartile range; SNNPR, Southern Nations,
Nationalities, and Peoples’ Region.
aAddis Ababa is a capital/charter city within the Oromia region.
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TABLE 2. Treatment Characteristics by Tumor Category
Cancer Type
No. of
Patients
Patients Who Received
Curative-Intent
Radiotherapy
Patients Who Received
Chemotherapy
Median Wait
Time
(days; Q1-Q3)
Patients Who Completed
Therapy Without
Interruption
Patients With Grade 3
or 4 Toxicitya
Brain, CNS 55 (3.0) 46 (83.6) 3 (5.5) 14 (0-60) 55 (100) 0
Earlyb stage 28 (50.9) 25 (89.2) 3 (10.7) 30 (0-112) 28 (100) 0
Latec stage 16 (29.1) 12 (75.0) 0 3.5 (0-30) 16 (100) 0
Locoregional
recurrence
4 (7.2) 3 (75.0) 0 45 (0-90) 4 (100) 0
Not reported 7 (12.7) 6 (13.0) 0 7 (0-30) 7 (100) 0
Breast 274 (15.0) 159 (58.0) 161 (58.8) 150 (0-240) 272 (99.3) 0
Early stage 44 (16.1) 44 (100) 23 (52.2) 180 (150-270) 43 (97.7) 0
Late stage 189 (68.9) 78 (41.2) 116 (61.3) 0 (0-210) 189 (100) 0
Locoregional
recurrence
41 (14.9) 37 (90.2) 22 (53.6) 300 (180-500) 40 (97.6) 0
GI 99 (5.0) 41 (41.4) 45 (45.5) 30 (0-150) 91 (91.9) 6 (6.0)
Early stage 14 (14.1) 14 (100) 10 (71.4) 120 (0-150) 12 (85.7) 2 (14.2)
Late stage 83 (83.8) 25 (30.1) 35 (42.1) 30 (0-150) 78 (94.0) 3 (3.6)
Locoregional
recurrence
2 (2.0) 2 (100) 0 105 1 (50.0) 1 (50.0)
Genitourinary 66 (4.0) 9 (13.6) 7 (10.6) 0 (0-0) 64 (97.0) 2 (3.0)
Early stage 2 (3.0) 2 (100) 1 (50) 120 2 (100) 0
Late stage 61 (92.4) 6 (9.8) 5 (8.1) 0 (0-0) 59 (96.7) 2 (3.3)
Locoregional
recurrence
3 (4.5) 1 (33.3) 1 (33.3) 0 3 (100) 0
Gynecologic 892 (49.0) 257 (28.8) 127 (14.2) 7 (0-90) 837 (93.8) 14 (1.6)
Early stage 201 (22.5) 176 (87.6) 64 (31.8) 90 (30-150) 193 (96.0) 6 (3.0)
Late stage 653 (73.2) 61 (9.3) 52 (7.9) 0 (0-30) 608 (93.1) 7 (1.1)
Locoregional
recurrence
37 (4.1) 19 (51.4) 11 (29.7) 90 (0-165) 35 (94.6) 1 (2.7)
Not reported 1 (0.1) 1 (0.4) 0 1 (100) 0
Head and neck 184 (10.0) 120 (65.2) 78 (42.4) 150 (0-210) 143 (77.7) 33 (17.9)
Early stage 13 (7.1) 13 (100) 2 (15.3) 150 (90-180) 11 (84.6) 1 (7.7)
Late stage 154 (83.7) 94 (61.0) 71 (46.1) 150 (30-210) 116 (75.3) 31 (20.1)
Locoregional
recurrence
10 (5.4) 6 (60.0) 4 (40.0) 165 (127-569) 9 (90.0) 1 (10.0)
Not reported 7 (3.8) 7 (5.8) 1 (1.3) 120 (30-180) 7 (100) 0
Hematologic 32 (2.0) 17 (53.1) 17 (53.1) 0 (0-0) 31 (97.0) 0
Early stage 11 (33.3) 11 (100) 5 (45.4) 0 (0-0) 11 (100) 0
Late stage 9 (28.1) 0 8 (88.8) 0 (0-0) 8 (88.9) 0
Locoregional
recurrence
4 (12.5) 3 (75.0) 2 (50.0) 0 (0-2) 4 (100) 0
Not reported 8 (25) 3 (17.6) 2 (11.8) 0 (0-0) 8 (100) 0
Sarcoma 64 (4.0) 27 (42.2) 31 (48.4) 1 (0-150) 62 (97.0) 1 (1.6)
Early stage 17 (26.6) 16 (94.1) 7 (41.2) 150 (60-210) 17 (100) 0
Late stage 33 (51.6) 4 (12.1) 19 (57.6) 0 (0-75) 33 (100) 0
Locoregional
recurrence
10 (15.6) 5 (50.0) 4 (40.0) 45 (0-129) 9 (90.0) 1 (10.0)
Not reported 4 (6.3) 2 (7.4) 1 (3.2) 1 (0-248) 3 (75.0) 0
(Continued on following page)
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(n = 32, 2.8%), neurologic symptoms (n = 25, 2.2%), other
(n = 3), and not reported (n = 263, 23%). The cancer
categories with highest percentage of curative intent in-
cluded brain and CNS (84%), head and neck (65%), breast
(58%), and hematologic malignancies (53%; Table 2). The
tumors least often treated with curative intent were thoracic
(lung and thymic, 0%), unknown primary (3%), thyroid
(4%), genitourinary (14%), and skin (18%). As expected,
patients who presented at an early stage were more likely
to be treated with curative intent. Twenty-seven percent of
patients (n = 494) received chemotherapy at some point in
their treatment; of these, the predominate cancer types
were breast cancer (59%), hematologic malignancies
(53%), sarcoma (48%), GI malignancies (45%), and head
and neck cancers (42%).
Treatment Completion and Toxicity
Ninety-four percent of patients (n = 1,710) completed
therapy without interruption, and 3% (n = 56) had docu-
mented grade 3 or 4 acute toxicity. Lowest rates of com-
pletion (without interruption) were in patients with head and
neck cancer (78%, n = 143), who also had the highest rates
of grade 3 or 4 acute toxicity (17.9%, n = 33).
Dosing Regimens
The most frequent RT regimen was 20 Gy in 2 fractions for
advanced-stage cervical cancer and 20 Gy in 5 fractions for
many other advanced-stage cancers (n = 672, 37%),
suggestive of palliative treatment (Table 3).
Wait Times
The wait times were the shortest for patients who received
short palliative treatment (median, 0 days; interquartile
range [IQR], 0-15 days; n = 1,138), whereas wait times
were long for patients who received curative treatment
(median, 150 days; IQR, 60-210 days; n = 685).
DISCUSSION
This cross-sectional study on the patterns of RT in Ethiopia
is, to our knowledge, the largest descriptive analysis of
RT use for all cancers in Ethiopia and, more broadly, the
African continent. In our cohort, women disproportion-
ally carried the cancer burden as a result of high rates of
breast and cervical cancer, consistent with published
data from the Addis Ababa population-based cancer
registry that breast and cervical cancer account for
nearly a third of all cancers, followed by colorectal cancer,
TABLE 2. Treatment Characteristics by Tumor Category (Continued)
Cancer Type
No. of
Patients
Patients Who Received
Curative-Intent
Radiotherapy
Patients Who Received
Chemotherapy
Median Wait
Time
(days; Q1-Q3)
Patients Who Completed
Therapy Without
Interruption
Patients With Grade 3
or 4 Toxicitya
Skin 33 (2.0) 6 (18.2) 10 (30.3) 7 (0-195) 33 (100) 0
Early stage 1 (3.0) 1 (100) 0 150 1 (100) 0
Late stage 24 (72.7) 1 (4.2) 6 (25.0) 0 (0-30) 24 (100) 0
Locoregional
recurrence
8 (24.2) 4 (50.0) 4 (50.0) 270 (165-349) 8 (100) 0
Thoracic 36 (2.0) 0 (0) 9 (25.0) 0 (0-0) 36 (100) 0
Early stage 0 0 0 0 0 0
Late stage 35 (97.2) 0 8 (22.9) 0 (0-0) 35 (100) 0
Locoregional
recurrence
1 (2.8) 0 1 (100) 0 1 (100) 0
Thyroid 57 (3.0) 2 (3.5) 2 (3.5) 0 (0-0) 56 (98.2) 0
Early stage 2 (3.5) 1 (50.0) 0 90 2 (100) 0
Late stage 52 (91.2) 0 2 (100) 0 (0-0) 50 (98.0) 0
Locoregional
recurrence
3 (5.2) 1 (50.0) 0 656 3 (100) 0
Unknown primary 31 (2.0) 1 (3.2) 5 (16.1) 0 (0-0) 30 (96.8) 0
Early stage 1 (3.2) 1 (100) 0 120 0 0
Late stage 30 (96.8) 0 5 (16.7) 0 (0-0) 30 (100) 0
Locoregional
recurrence
0 0 0 0 0 0
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviation: Q, quarter.
aBased on Common Terminology Criteria for Adverse Events version 5.0.
bEarly stage indicates American Joint Committee on Cancer (AJCC)/International Federation of Gynecology and Obstetrics (FIGO) stage I or II or operative
sarcoma or CNS tumor.
cLate stage indicates AJCC/FIGO stage III or IV or nonoperative sarcoma or CNS tumor.
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non-Hodgkin lymphoma, leukemia, prostate cancer, and
thyroid cancer.11,14,15 According to the International Agency
for Research on Cancer, cervical cancer is the fourth most
common cancer in women worldwide, but it is the most
frequent cancer in women in many countries in sub-
Saharan Africa where incidence is the highest in the
world. This is a stark disparity because 85% of women
diagnosed with cervical cancer (a largely avoidable dis-
ease) live in LMICs with limited access to preventative
services and treatment.16-18
The prevalence of HIV in our cohort was 3-fold higher than
that of the general Ethiopian population (4.6% v 1.5%,
respectively), which has also been observed in Uganda.19,20
A majority of patients in the study were female. Females
have a higher prevalence of HIV than males; in addition,
HIV is an independent risk factor for cervical cancer, which
is preferentially treated by RT. A study by Kantelhardt et al21
reported a 9% prevalence of HIV in Ethiopian patients with
cervical cancer, and our study found a similar rate in
Ethiopian patients with gynecologic cancers. These HIV
rates in patients with cervical cancer are lower compared
with other countries in sub-Saharan Africa as a result of the
overall lower prevalence of HIV in Ethiopia.22,23
Nearly three-quarters of all patients with cancer in this
study presented at late stage, which is consistent with
ﬁndings from other countries in sub-Saharan Africa. This is
at least partially a result of the lack of national screening
programs in most African regions.24-26 In addition, a great
majority of cancer care in Ethiopia is centralized to the
tertiary level of care. Even palliative care services are
centralized and not initiated until a patient is seen at TASH,
a system that is critically over capacity. Our study not only
emphasizes the need for high-impact, low-cost prevention
and screening strategies in Ethiopia and the African con-
tinent at large, with the aim of diagnosing cancer at early
stages when RT and other treatment modalities can be
used with curative intent, but also emphasizes the need
to decentralize palliative care and train primary- and
secondary-level providers to provide palliative care at the
community level.
In most cases of palliative RT, patients returned to their
communities and were not seen in follow-up; therefore,
documented toxicity was overall low. Patients with head
and neck cancer had the highest rates of treatment in-
terruption and the highest rates of grade 3 or 4 toxicity,
which is similar to the literature.27 To our knowledge, there
are no other published reported rates of acute RT toxicity in
head and neck cancer in sub-Saharan Africa. Moelle et al28
reported grade 3 early toxicity in 5% of patients with cervical
cancer who received curative RT in the same center in
Ethiopia, which was a considerably higher rate than in this
study. This is at least partially a result of the addition of
brachytherapy during our study period, which alleviates the
need for an external-beam boost, causing higher toxicity to
the surrounding tissue.
One of the most striking ﬁndings of this study was the long
waiting times of patients with potential for cure. Waiting
times are inﬂuenced by the priority given to the large
burden of patients who require palliation of debilitating
symptoms such as pain, obstruction, or bleeding and risk
reduction of emergent conditions such as pathologic
fracture and cord compression. In addition, priority is given
to younger patients. These reasons, coupled with limited
treatment availability, played a major role in the observed
wait times. This situation leads to a long wait for many
individuals with potentially curative disease, risking their
conversion to the palliative category as the disease prog-
resses. Kantelhardt et al21 showed comparable rates of
late-stage cervical cancer and wait times in Ethiopia but
also reported that the proportion of patients with late-stage
cervical cancer (FIGO stage IIIb and greater) increased
from 44% to 69% during the wait time. In our study, stage
was recorded immediately before starting RT; therefore,
the rates of conversion during the wait time are unknown;
however, it is possible that a 20% conversion also occurred
TABLE 3. Most Common dosing Regimen by Diagnosis
Diagnosis and Dosing Regimen
No. of Patients
(%)
Cervical cancer 851
Early stage 197
Pelvis, 40-50 Gy in 2-Gy fractions + brachytherapy 91 (46)
Pelvis, 40-50 Gy in 2-Gy fractions +
20-26 Gy in 2-Gy fraction boosta
55 (30)
Late stage 621
Pelvis, 20 Gy in 10-Gy fractions 387 (62)
Locoregional recurrence 32
Pelvis, 46 Gy in 2-Gy fractions 9 (28)
Breast cancer 274
Early stage 44
Chest wall, 39 Gy in 3-Gy fractions 6 5-16 Gy in 2-Gy
fraction boost
38 (86)
Late stage 189
Bone or brain, 20 Gy in 5-Gy fractionsb 89 (47)
Locoregional recurrence 41
Chest wall, 39 Gy in 3-Gy fractions 6 10-18 Gy in 2-Gy
boost
26 (63)
Head and neck cancer 184
Early stage 13
Head and neck, 66-70 Gy in 2-Gy fractions 7 (54)
Late stage 154
Head and neck, 60-70 Gy in 2-Gy fractions 90 (58)
Locoregional recurrence 10
Head and neck, 60-66 Gy in 2-Gy fractions 6 (60)
aStandard regimen before brachytherapy capacity.
bDosing for metastatic disease.
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during the waiting times. A correlation has been made
between long wait time and worse outcomes in head and
neck cancer; a Taiwanese study showed worse outcomes
after 40-day delay, and a larger Dutch study showed worse
outcome after 90 days.29,30 The median wait time for
radical and adjuvant head and neck cancer was 5months.
This ﬁnding is of importance because it calls for better
planning and stratiﬁcation of treatment in an attempt to
increase cure rates for early-stage tumors. It is likely that
as more RT equipment is available in the region, waiting
times will decrease and better curative-intent stratiﬁcation
will occur.
In regard to RT dosing at TASH, conventional fractionation
is preferred for all curative diagnoses except for breast
cancer, for which the hypofractionation schedule is used
based on the START-A trial to maximize limited RT
resources.31 Since brachytherapy was obtained in 2016, all
curative patients are receiving brachytherapy unless probe
insertion is not possible. Furthermore, because of limited
capacity, concurrent chemoradiation is not yet feasible for
cervical cancer.
There are multiple limitations to this study. First, the ret-
rospective nature narrows the qualitative descriptors of the
data to those previously recorded in the patient ﬁle. Second,
the data collection was completed after approximately half
of the estimated cohort was enrolled as a result of feasibility
because data analysis at 1,823 patients was unchanged
from data analysis after 500 patients, indicating a ran-
dom sample. Third, cancer staging was performed by the
treating physician through standardized methods agreed
upon throughout the department. However, the eighth and
latest edition of the AJCC staging system was not used
because of lack of molecular diagnostics. For example,
estrogen receptor–, progesterone receptor–, and human
epidermal growth factor receptor–status is not routinely
determined in patients with breast cancer. However, this
is a limitation applicable to many resource-limited areas
and speaks of the need to create differential guidelines
in these settings. Finally, the availability of documented
follow-up data were rare; thus, late toxicities and patient
outcomes were not available. Information about acute
toxicity was also not routinely recorded and likely signiﬁ-
cantly underreported, highlighting the need for future
prospective studies that can more accurately describe
toxicity and outcomes. Because more RT equipment needs
to be purchased, it is imperative for stakeholders to have
accurate outcome information from the African context
about different equipment choices to help inform decisions.
To our knowledge, this study is the largest of its kind,
describing the basic epidemiology and ﬁndings of more
than 1,800 patients treated with cobalt RT at a large referral
hospital in sub-Saharan Africa. Most patients were treated
for gynecologic cancer and presented at advanced stage.
The goal of treatment was palliative in a majority of patients,
and limited radiation capacity led to long waiting times. The
need for increased RT capacity is critical, and future
prospective studies are needed on outcomes for RT mo-
dalities in sub-Saharan Africa.
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